Furberg C D, Hawkins C M, Lichstein E
Circulation. 1984 Apr;69(4):761-5. doi: 10.1161/01.cir.69.4.761.
In "post hoc" subgroup analyses, a simple classification system for patients, based on the presence or absence of findings indicative of electrical and/or mechanical complications early during short-term hospitalization, was applied to the data from the Beta-Blocker Heart Attack Trial (BHAT). In the largest subgroup of BHAT patients who had no reported complications, the 25 month mortality was low and the observed benefit of propranolol therapy small. Patients with electrical complications only had intermediate mortality and a pronounced effect of treatment was observed. Those with mechanical complications had the highest mortality and experienced an intermediate relative benefit of beta-blocker treatment. They also reported the most adverse effects. Post hoc analyses should always be interpreted cautiously. It is important to determine whether these findings are present in other completed beta-blocker trials. On the basis of these analyses alone it is suggested that the present practice of prescribing beta-blockers in postinfarction patients should not be altered.
在“事后”亚组分析中,基于短期住院早期是否存在提示电气和/或机械并发症的检查结果,对患者采用了一种简单的分类系统,并将其应用于β受体阻滞剂心肌梗死试验(BHAT)的数据。在BHAT中未报告并发症的最大亚组患者中,25个月死亡率较低,普萘洛尔治疗的观察到的益处较小。仅出现电气并发症的患者死亡率中等,且观察到治疗有显著效果。出现机械并发症的患者死亡率最高,β受体阻滞剂治疗的相对益处中等。他们报告的不良反应也最多。事后分析应始终谨慎解释。确定这些结果是否存在于其他已完成的β受体阻滞剂试验中很重要。仅基于这些分析,建议不应改变目前在心肌梗死后患者中开具β受体阻滞剂的做法。